Pharmaceuticals news FT.com

New Novo Nordisk drug could beat market leaders for weight loss, early results show

Participants in trial of amycretin injectable obesity drug lost an average of 24% of their body weight on highest dose

Jun 21, 2025 - 01:45
 0
New Novo Nordisk drug could beat market leaders for weight loss, early results show
Participants in trial of amycretin injectable obesity drug lost an average of 24% of their body weight on highest dose
Read More

Tags:

Previous Article

FDA Approves Twice-Yearly Yeztugo for Preexposure Prophylaxis to Cut HIV Risk

Next Article

STAT+: Full data on Novo Nordisk’s new amylin drug raise dosing questions

Related Posts

Trump vows to lower US drug prices by up to 80%

Trump vows to lower US drug prices by up to 80%

May 12, 2025  0

Novo Nordisk chief Jørgensen to step down

Novo Nordisk chief Jørgensen to step down

May 16, 2025  0

Trade war could put the frown back on Botox users’ faces

Trade war could put the frown back on Botox users’ faces

May 12, 2025  0